

Developmental Biology

A *MSTN*^{Del273C} mutation with *FGF5* knockout sheep by CRISPR/Cas9 promotes skeletal muscle myofiber hyperplasia via MEK-ERK-FOSL1 axis

Reviewed Preprint

Published from the original preprint after peer review and assessment by eLife.

About eLife's process

Reviewed preprint posted

June 23, 2023 (this version)

Posted to bioRxiv

March 9, 2023

Sent for peer review

March 9, 2023

Ming-Ming Chen, Yue Zhao, Xue-Ling Xu, Xiao-Sheng Zhang, Jin-Long Zhang, Su-Jun Wu, Zhi-Mei Liu, Yi-Ming Yuan, Xiao-Fei Guo, Shi-Yu Qi, Guang Yi, Shu-Qi Wang, Huang-Xiang Li, Ao-Wu Wu, Guo-Shi Liu, Kun Yu, Shoulong Deng, Hong-Bing Han, Feng-Hua Lv , Yan Li , Zheng-Xing Lian 

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China • Institute of Animal Husbandry and Veterinary Medicine, Tianjin Academy of Agricultural Sciences, Tianjin 300381, China • NHC Key Laboratory of Human Disease Comparative Medicine, Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China • Laboratory Animal Center of the Academy of Military Medical Sciences, Beijing 100071, China

 (https://en.wikipedia.org/wiki/Open_access)

 (<https://creativecommons.org/licenses/by/4.0/>)

Abstract

Mutations in the well-known Myostatin (*MSTN*) produce a “double-muscle” phenotype, which makes it commercially invaluable for improving livestock meat production and providing high-quality protein for humans. However, mutations at different loci of the *MSTN* often produce a variety of different phenotypes. In the current study, we increased the delivery ratio of Cas9 mRNA to sgRNA from the traditional 1:2 to 1:10, which improves the efficiency of the homozygous mutation of biallelic gene. Here, a *MSTN*^{Del273C} mutation with *FGF5* knockout sheep, in which the *MSTN* and *FGF5* dual-gene biallelic homozygous mutations were produced via the deletion of 3-base pairs of AGC in the third exon of *MSTN*, resulting in cysteine-depleted at amino acid position 273, and the *FGF5* double allele mutation led to inactivation of *FGF5* gene. The *MSTN*^{Del273C} mutation with *FGF5* knockout sheep highlights a dominant “double-muscle” phenotype, which can be stably inherited. Both F0 and F1 generation mutants highlight the excellent trait of high-yield meat with a smaller cross-sectional area and higher number of muscle fibers per unit area. Mechanistically, the *MSTN*^{Del273C} mutation with *FGF5* knockout mediated the activation of *FOSL1* via the MEK-ERK-FOSL1 axis. The activated *FOSL1* promotes skeletal muscle satellite cell proliferation and inhibits myogenic differentiation by inhibiting the transcription of *MyoD1*, and resulting in smaller myotubes.

eLife assessment

The authors present a **useful** analysis of the phenotype of sheep in which the muscle developmental regulator myostatin has been mutated in a *FGF5* knockout background. The goal was to produce sheep with a "double-musced" phenotype, yet the genetically engineered sheep exhibited meat with a smaller cross-sectional area and higher number of muscle fibers. The work extends the extensive body of knowledge already published in this area. The authors provide evidence using in vitro experiments that *Fosl1* regulates myogenesis, but the strength of evidence relating to the muscle phenotype and underlying cellular and molecular mechanism is **inadequate**.

1 Introduction

Myostatin (*MSTN*) has been well-known as a negative regulator of muscle growth and development. Its mutation produces a "double-muscle" phenotype, which shows its inestimable commercial value in improving meat production of livestock and poultry, and providing high-quality protein for humans (Fan *et al.*, 2022; Chen *et al.*, 2021b). Due to its role in promoting muscle atrophy and cachexia, *MSTN* has been recognized as a promising therapeutic target to offset the loss of muscle mass (Lee, 2021; Baig *et al.*, 2022; Wijaya *et al.*, 2022).

MSTN is highly conserved in mammals, and mutations in the *MSTN* gene, either artificially or naturally, will result in increased skeletal muscle weight and produce a "double-muscle" phenotype, which has been reported in many species, including cattle, sheep, and pigs, rabbits, and humans (Grisolia *et al.*, 2009; Dilger *et al.*, 2010; Kambadur *et al.*, 1997). However, mutations at different loci of the *MSTN* often produce variety of different phenotypes, and its molecular mechanism of skeletal muscle growth and development remains controversial (Hanset and Michaux, 1985; Grobet *et al.*, 1997; Wegner *et al.*, 2000; Kambadur *et al.*, 1997; Marchitelli *et al.*, 2003). More than 77 natural mutation sites of *MSTN* have been reported in various sheep breeds, most of these mutations were found to be located in the non-coding regions, and did not affect *MSTN* activity (Kijas *et al.*, 2007; Sjakste *et al.*, 2011; Han *et al.*, 2013; Dehnavi *et al.*, 2012). In addition to introns, it is still possible that mutations in regulatory regions and exons may not affect the sheep phenotypes (Pothuraju *et al.*, 2015; Kijas *et al.*, 2007; Boman and Vage, 2009; Boman *et al.*, 2009).

Fibroblast growth factor 5 (*FGF5*) belongs to the fibroblast growth factor (FGF) family and is a secretory signaling protein. *FGF5* played an inhibitory effect on mouse hair growth (Hebert *et al.*, 1994), and its natural mutation can lead to a significant increase in hair growth in angora mice (Sundberg *et al.*, 1997). Subsequent studies have also successively confirmed the inhibitory effect of *FGF5* on mammalian hair growth and is recognized to be a negative regulator of hair growth (Kehler *et al.*, 2007; Dierks *et al.*, 2013; Yoshizawa *et al.*, 2015; Legrand *et al.*, 2014; Higgins *et al.*, 2014).

FOS-like 1 (FOSL1), also named Fos-related antigen 1 (FRA1), is a member of the Fos subfamily of activator protein 1 (AP-1) superfamily. The Fos family proteins are involved in cell proliferation, differentiation, and transformation. FOSL1 and even AP-1 family members are generally recognized to be related to various cancers. However, accumulating evidence indicate that AP-1 family proteins play a critical role in skeletal muscle cell proliferation,

differentiation, and muscle development (Puntschart *et al.*, 1998; Liu *et al.*, 2010). FOSL1 has also been characterized as an important component of the response of skeletal muscle during aging and a lipid biosynthesis-related factor (Mathes *et al.*, 2021; Wang *et al.*, 2017). Furthermore, FOSL2 and c-Jun, another member of the AP-1 family, were found to inhibit myoblast differentiation (Alli *et al.*, 2013; Bengal *et al.*, 1992). In all, it is foreseeable that the role of FOSL1 in myogenesis will increasingly emerge.

In this study, to increase both meat and wool production, we first produced the *MSTN* and *FGF5* dual-gene biallelic homozygous mutations sheep by the increased delivery ratio of Cas9 mRNA to sgRNA targeting *MSTN* and *FGF5*. The *MSTN*^{Del273C} mutation with *FGF5* knockout sheep highlights a dominant “double-muscle” phenotype by decreasing the muscle fiber cross-sectional area and increasing the number of muscle fibers per unit area. Then, we used the *MSTN* and *FGF5* dual-gene biallelic homozygous mutations sheep to unravel the molecular mechanism of the “double-muscle” phenotype and myofiber hyperplasia.

2 Materials and Methods

2.1 Tissue sample collection and preparation

Gluteus medius and longissimus dorsi were harvested from WT and *MSTN*^{Del273C} mutation with *FGF5* knockout (MF^{-/-}) sheep, and three WT sheep and four MF^{-/-} F1 generation sheep (half-sib) were used for feeding and slaughter. All samples were immediately frozen in liquid nitrogen and then stored at -80°C until analysis. All sheep are raised by the national feeding standard NT/T815-2004. All procedures performed for this study were consistent with the National Research Council Guide for the Care and Use of Laboratory Animals. All experimental animal protocols in this study were approved and performed following the requirements of the Animal Care and Use Committee at China Agricultural University (AW02012202-1-3). All surgeries were performed under sodium pentobarbital anesthesia, and all efforts were made to minimize any suffering experienced by the animals used in this study.

2.2 Cell isolation, culture, and transfection

Sheep skeletal muscle satellite cells were isolated and cultured as previously described (Chen *et al.*, 2021a). In brief, the muscle tissues of the hind limbs from 3-month-old sheep fetuses were cut into small pieces, digested with 0.2% collagenase type II (Gibco, Grand Island, NY) at 37°C for 1 h, and then centrifuged at 1000 rpm for 10 min. The precipitates were continued digested with 0.25% trypsin (Gibco, Grand Island, NY) at 37°C for 30 min, and digestion was terminated with serum containing medium. The cell suspension was successively filtered through 100, 200 and 400 mesh cell sieves. After this, the cells were centrifuged at 1000 rpm for 10 min, resuspended in growth medium (GM) containing DMEM/F12 (Gibco, Grand Island, NY) with 20% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin liquid (Gibco, Grand Island, NY), and cultured for 2-3 times with differential adhesion. To induce differentiation, the cells were cultured to 70% confluence in GM, and followed by an exchange to differentiation medium (DM) containing DMEM high glucose (Gibco, Grand Island, NY) with 2% horse serum (HS, Gibco) and 1% penicillin-streptomycin liquid to culture 24 h, 48 h, and 72 h. To produce viral solution for over-expression of the target gene, it was subcloned into the XbaI and BamHI sites of the lentiviral vector by seamless cloning. HEK 293T cells were co-transfected with the envelope plasmid pMD2.G, the packaging plasmid psPAX2 and the target plasmid at a mass ratio of 1:2:4. Then, the culture medium was collected at 48h and 72h after transfection, and the cell

debris was removed by filtration. Then, the sheep skeletal muscle satellite cells were infected with packaged lentivirus when they were cultured to 60%-70% confluence in 96-well, 24-well or 6-well plates. Finally, cells were collected for analysis after infection at 24 h or 48 h. All the primer sequences of gene cloning were listed in Table S1.

2.3 Total RNA isolation and real-time quantitative PCR (RT-qPCR)

The total RNA of tissues and cells was isolated using TRIzol reagent (Sangon Biotech, Shanghai, China) following the manufacturer's protocol. In short, after tissues or cells were lysed, chloroform was added to separate the organic and inorganic phases, followed by precipitation with isopropanol and ethanol in turn, and finally, the RNA was dissolved in DEPC water. Then, the first strand cDNA was prepared using PrimeScript II 1st Strand cDNA Synthesis Kit (Takara, Beijing, China). qPCR was performed using 2× SYBR Green qPCR Mix (Low ROX) (Aidlab Biotechnologies, Beijing, China) in a Stratagene Mx3000P (Agilent Technologies, USA). With GAPDH mRNA as endogenous control, the relative expression level of genes was calculated by the $2^{-\Delta\Delta C_t}$ method. All primers used were listed in Table S2.

2.4 Western blot

Tissue or cell samples were lysed in RIPA buffer (Solarbio, Beijing, China) supplemented with protease and phosphatase inhibitor cocktail (Beyotime, Beijing, China) for total protein extraction. Then, equal amounts of tissue or cell lysate were resolved by 10% SDS-PAGE and transferred onto PVDF membranes (Millipore, USA). The membranes were blocked with 5% BSA for 1h, incubated with primary antibody at 4°C overnight, then incubated with secondary antibody for 1h before detection. The fold change of protein was normalized to GAPDH for quantitative analysis by ImageJ software. The antibodies information was listed in Table S3.

2.5 5-Ethynyl-2'-deoxyuridine (EdU) assay

At 24 h after transfection, sheep skeletal muscle satellite cells were incubated at 37°C for 2 h in 96-well plates with 50 μM EdU (RiboBio, Guangzhou, China). Then, fixed the cells in 4% paraformaldehyde for 30 min and neutralized using 2 mg/mL glycine solution. The Apollo® staining solution which contains EdU was added and incubated at room temperature for 30 min in the dark to label the DNA in the synthesis stage, the nuclear was then counterstained with DAPI. The number of EdU positive cells was counted from the images of five random fields obtained with an inverted fluorescence microscope at a magnification of 100×. EdU labeling index was expressed as the number of EdU-positive cell nuclei/total cell nuclei.

2.6 Cell counting kit-8 (CCK-8) and cell cycle detection

Skeletal muscle satellite cells were seeded in 96-well plates and cultured for appropriate time according to different experimental treatments. Then, 10 μL CCK-8 solution was added to each well and incubated at 37°C in a 5% CO₂ incubator for 2 h, and then the absorbance at 450 nm was measured with a microplate reader.

The cultured skeletal muscle satellite cells were digested with trypsin, centrifuged at 1000 g for 5 min to collect the cell pellet, washed once with ice-cold PBS, and then 1 mL of ice-cold 70% ethanol was added to fix the cells overnight at 4°C. The next day, the cells were washed with ice-cold PBS again, and the cells were incubated with 0.5 mL PI staining solution at 37°C for 30 min and collected by flow cytometry at low speed.

2.7 Immunofluorescence staining

Sheep skeletal muscle cells were fixed in 4% paraformaldehyde for 30 min, permeabilized in 0.1% Triton X-100 for 20 min and blocked with 5% normal goat serum for 30 min at room temperature, and then incubated with primary antibody at 4°C overnight. Next, the fluorescent secondary antibody was added and incubated at 37°C for 1 h in the dark, and the nuclear was then counterstained with DAPI. The immunofluorescence images from five random fields were captured with an inverted fluorescence microscope.

2.8 Chromatin Immunoprecipitation (ChIP)

The cells were fixed with 1% formaldehyde for 10 min at room temperature, then neutralized with 1× glycine solution for 5 min, and washed twice with ice-cold PBS. Then, the cells were collected with a cell scraper and resuspended in 0.5 mL cell lysis buffer (10 mM HEPES, 0.5% NP-40, 1.5 mM MgCl₂, 10 mM KCl, pH 7.9) containing protease inhibitor cocktail (Beyotime, Beijing, China) and incubated on ice for 15 min to release the cytoplasm. Next, cell pellets were collected by centrifugation at 800 g for 5 min at 4°C and resuspended in 0.5 mL nuclear lysis buffer (50 mM Tris, 10 mM EDTA, 0.3% SDS, pH 8.0) containing protease inhibitor cocktail. After the DNA was fragmented by ultrasonication, the suspension was centrifuged at 4°C 12000g for 10 min, and the supernatant was collected. And 50 µL supernatant of each sample was diluted with 450 µL of ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.0, 167 mM NaCl), then 5 µg primary antibody was added and incubated overnight at 4°C with rotation. The next day, 20 µL protein A/G magnetic beads were added to each sample and incubated at 4°C with rotation for 2h. Then, the magnetic beads were respectively washed once with low-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 150 mM NaCl), high-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500mM NaCl, 20 mM Tris-HCl pH 8.0), LiCl wash buffer (0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.0), and TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA) at 4°C, and the supernatant was discarded. Next, 100 µL ChIP elution buffer (1% SDS, 100 mM NaHCO₃) containing proteinase K was added to each sample, then incubated at 62°C overnight, and the DNA was finally purified by a purification column.

2.9 RNA-seq

The rRNA was removed from each total RNA sample of the gluteus medius to construct a strand-specific transcriptome sequencing library, and the Illumina Novaseq 6000 sequencing platform was used to perform high-throughput sequencing with a paired-end read length of 150 bp. Raw data were transformed into clean reads by removing reads containing adapter, ploy-N and low-quality reads from raw data. At the same time, Q20, Q30, GC-content, and sequence duplication levels of the clean data were calculated. The genome index was constructed using Hisat2 software and the clean reads were mapped to the sheep reference genome (*Oar Rambouillet v1.0*), the featureCounts software was used for expression quantification, and DESeq2 software was used for differential expression analysis based on P -value < 0.05 and $|\log_2 \text{Fold Change}| > 1$.

2.10 Statistical analysis

All results are presented as the mean ± SEM. Statistical analyses of differences between groups were performed using a two-tailed *Student's t*-test or chi-square test and $P < 0.05$ was considered statistically significant. * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$.

3 Results

3.1 Elevated molar ratio of Cas9/sgrNA can efficiently generate biallelic homozygous mutant sheep

The sgRNAs for targeting were designed in the third exon of the MSTN and FGF5 genes, respectively, to generate mutant MSTN gene for quality trait improvement and mutant FGF5 gene for yield trait improvement sheep by CRISPR/Cas9 gene editing technology (Figure 1A, B). Both MSTN and FGF5 PCR products could be cleaved by T7E1 and the fragment sizes were also as expected, and grayscale analysis showed that the editing efficiency was 14.6% and 11.4%, respectively (Figure 1C), which indicates that the designed sgRNAs can achieve more efficient gene targeting.




Figure 1

Efficient generation of sheep carrying biallelic mutations in dual gene via the CRISPR/Cas9 system


(A) Schematic of sgRNAs specific to exon 3 of the sheep MSTN locus. The crRNA sequences are highlighted in blue typeface and the PAM in red. (B) Schematic of sgRNAs specific to exon 3 of the sheep FGF5 locus. The crRNA sequences are highlighted in blue typeface and the PAM in red. (C) T7EI assay for sgRNAs of MSTN and FGF5 in sheep fetal fibroblasts. The cleavage bands are marked with a red asterisk (*) and the indel frequencies were calculated using the expected fragments. (D) Summary of the generation of sheep carrying biallelic mutations in dual gene via zygote injection of Cas9 mRNA/sgRNAs. (E) Analysis of genome sequence and amino acid sequence of MSTN-modified sheep. The location of sgRNA and PAM are highlighted in blue and red, respectively. The deletions are indicated by a dashed line (-). (F) Analysis of genome sequence and amino acid sequence of FGF5-modified sheep. The location of sgRNA and PAM are highlighted in blue and red, respectively. The deletions are indicated by a dashed line (-).

The microinjection was performed according to the injection molar ratio of Cas9 mRNA:sgRNAs (1:2, 1:10, and 1:15), respectively. The number of embryos injected, recipients of nuclear transfer, pregnancy, and alive lambs per group were listed in Table S4. The subsequent gene mutation detection showed that a total of 3 lambs were mutated in the MSTN and FGF5 genes at a Cas9 mRNA:sgRNAs injection molar ratio of 1:2, with a gene editing mutation rate of 14.3% (4/28). However, all 3 lambs were chimeric, that is, there were both mutant and wild-type after editing, and the biallelic mutation rate was 0% (Table S4, [Figure 1D](#)). When the injection molar ratio of Cas9 mRNA:sgRNAs was 1:10, two lambs were

mutated in *MSTN* and *FGF5* genes, and the mutation rate of gene editing was 18.2 % (4/22). And these two lambs were all double-gene biallelic homozygous mutant lambs, that is, the alleles on the homologous chromosomes were mutated after the target gene was edited (Table S4, Figure 1D). While the injection molar ratio of Cas9 mRNA: sgRNAs was continuously increased to 1:15, one lamb had a mutation, which was a biallelic mutation of *MSTN* gene, and the gene editing mutation rate was 7.14% (1/14) (Table S4, Figure 1D). All the mutation forms of bases and amino acids in *MSTN* and *FGF5* genes are shown in Figure 1E and Figure 1F, respectively. These results indicate that increasing the delivery molar ratio of Cas9 mRNA to sgRNA from 1:2 to 1:10 can greatly improve the efficiency of biallelic mutation in sheep.

3.2 The *MSTN*^{Del273C} mutation with *FGF5* knockout sheep highlights a dominant “double-muscle” phenotype and muscle fiber hyperplasia

Among gene-edited sheep, a sheep with biallelic deletion of *MSTN* and biallelic mutation of *FGF5* aroused our great interest. Specifically, gene editing caused a deletion of 3-base pairs of AGC in the third exon of *MSTN* (Figure 1E, F), resulting in the deletion of cysteine at amino acid position 273 (*MSTN*^{Del273C}) (Figure 1E, F), which is highlighted by the “double-muscle” phenotype (Figure 2A, 2B). At the same time, a biallelic mutation in *FGF5* caused the knockout of *FGF5* gene and increased the density and length of hairs (Zhang *et al.*, 2020). Given the prominent “double-muscle” phenotype of MF^{-/-} sheep, we examined its histological morphology of the gluteus medius and longissimus dorsi, and found that the fiber cell number per unit area of muscle tissue in MF^{-/-} sheep was significant ($P < 0.01$) higher than that in WT sheep (Figure 2C, D). Further, we also found that the percentage of smaller myofiber in the gluteus medius and longissimus dorsi was clear higher in MF^{-/-} sheep than that in WT sheep, whereas the percentage of larger muscle fiber area was lower (Figure 2C, E, F). To determine whether this phenomenon was affected by *FGF5* gene mutation, we also separately examined the muscle fiber morphology in *FGF5* knockout sheep alone and found that *FGF5* knockout alone had no significant ($P > 0.05$) effect on muscle fiber size (Figure S1). All these results demonstrated that the dual-gene biallelic mutation MF^{-/-} sheep had well-developed hip muscles with smaller muscle fibers, and this phenotype was dominated by *MSTN* gene.



area in WT and MF^{+/-} sheep. (K) The percentage of cross-sectional area of different size muscle fibers.

To further determine the heritability of the above phenotypes, we crossed MF^{-/-} sheep with homozygous WT sheep to produce the offspring generation of MF^{+/-} sheep, which were identified that the gene editing could be stably inherited to the offspring, and they were all mutant heterozygotes of *MSTN* and *FGF5* monoalleles (MF^{+/-}) (Figure S2). Subsequently, 3 WT sheep and 4 MF^{+/-} sheep were slaughtered. Compared to WT sheep, the proportion of rib meat was significantly reduced in MF^{+/-} sheep, and the proportion of hind leg meat was significantly increased, the ratio of hind leg meat increased by 21.2% (Table 1). Further, the muscle weight of different parts in WT and MF^{+/-} sheep has no significant difference (Table S5). However, the proportion of gluteus medius in the carcass of MF^{+/-} sheep was significantly ($P < 0.01$) increased, with a 26.3% increase compared to WT sheep (Figure 2G). In addition, there were no significant ($P > 0.05$) differences in pH, color, drip loss, cooking loss, shearing force, and amino acid content of the longissimus dorsi between WT and MF^{+/-} sheep (Table S6-8). Compared with WT sheep, the cross-sectional area of gluteus medius muscle fibers in MF^{+/-} sheep was also smaller (Figure 2H-I), and the number of muscle fiber cells per unit area was significantly increased ($P < 0.001$) (Figure 2H, J); the percentage of

smaller muscle fiber area in MF^{+/-} sheep was significantly increased ($P<0.05$), while the percentage of larger muscle fiber area was significantly decreased ($P<0.05$) (Figure 2H, K), these results was consistent with that in MF^{-/-} sheep. All these results demonstrated that the dual-gene biallelic editing of the *MSTN* and *FGF5* could be stably inherited by the offspring, and the later generation characterized excellent traits of high-yield meat.

Table 1

The slaughter traits of muscles in WT and MF^{+/-} sheep

Slaughter Indexes	WT (n=3)	MF ^{+/-} (n=4)	P-value
Live weight (kg)	56.33±3.088	50.15±2.058	0.14201
Carcass weight(kg)	32.23±2.436	28.5±1.588	0.23588
Slaughter percentage (%)	57.12±1.237	56.75±1.259	0.84403
loin muscle area (cm ²)	17.17±1.58	13.95±1.757	0.24795
Meat weight (kg)	18.79±1.306	15.68±0.825	0.08707
The proportion of meat in carcass	0.58±0.005	0.55±0.018	0.18691
The proportion of brisket and neck meat	0.14±0.018	0.13±0.004	0.85322
The proportion of loin meat	0.11±0.005	0.09±0.011	0.33339
The proportion of rib meat	0.22±0.004	0.15±0.003	0.00003
The proportion of foreleg meat	0.18±0.009	0.21±0.012	0.20974
The proportion of hind leg meat	0.33±0.009	0.4±0.016	0.0252
Neat percentage (%)	0.58±0.005	0.55±0.018	0.18691

3.3 The *MSTN*^{Del273C} mutation with *FGF5* knockout promotes skeletal muscle satellite cells proliferation and inhibits myogenic differentiation

Given that the *MSTN*^{Del273C} mutation with *FGF5* knockout produced the phenotype of “double-muscle” and reduced muscle fiber cross-sectional area, we detected the in-situ expression of MSTN protein. The results showed that there was no significant differential expression of MSTN protein in both gluteus medius and longissimus dorsi of MF^{-/-} sheep compared with WT sheep (Figure S3A). Also, there was no significant difference in MSTN mRNA (Figure S3B) and protein expression (Figure S3C-D) in gluteus medius of WT and MF^{+/-} sheep. Further immunofluorescence also revealed no significant difference in MSTN protein expression in both myoblasts and myotubes (Figure S3E). These results suggested that the *MSTN*^{Del273C} mutation with *FGF5* knockout does not affect the normal expression of *MSTN*.

The proliferation and differentiation of skeletal muscle satellite cells is a key step in muscle formation and development. The CCK-8 and EdU cell proliferation experiments showed that the proliferative rate of MF^{+/-} cells were highly significantly ($P<0.01$) elevated (Figure 3A) with a significant ($P<0.05$) increase in the rate of EdU-positive cells (Figure 3B, C) compared to WT cells. In addition, cell cycle detection showed a significant ($P<0.01$) reduce in the proportion of G1 phase and a significant increase ($P<0.05$) in the proportion of S phase in MF^{+/-} cells (Figure 3D, E). Meanwhile, the mRNA expression levels of the cell cycle marker genes CyclinB1, CDK4, Cyclin A1, Cyclin E1, and CDK2 were significantly increased ($P<0.05$) (Figure 3F). These results suggest that the *MSTN*^{Del273C} mutation with *FGF5* knockout may promote cell proliferation by accelerating the cell cycle from G0/G1 phase to S phase.




Figure 3

The MSTN^{Del273C} mutation with FGF5 knockout promote proliferation and inhibit differentiation of skeletal muscle satellite cells

(A) The number of cells was detected by CCK-8 at 12h, 24h, 36h, 48h, and 60h in GM. (B-C) EdU assay showed that the number of EdU positive cells and EdU labeling index were significantly increased in MF^{+/-} cells. Scale bar 130 μm. (D-E) PI staining to detect cell cycle and showed a significant reduce in the proportion of G1 phase and a significant increase in the proportion of S phase in MF^{+/-} cells. (F) The mRNA expression levels of cell cycle marker genes and cell proliferation marker genes. (G) The mRNA expression levels of myogenic differentiation marker genes MyoG, MyoD1, and MyHC. (H-I) The protein expression levels of myogenic differentiation marker genes MyoG, MyoD1, and MyHC. (J) The MyoG and MyHC immunofluorescence staining of myotubes in DM2. Scale bar 130 μm. (K) The myotube fusion index, which was represented by the number of cell nuclei in myotubes/total cell nuclei. (L) The number of my-

otubes, which was the number of all myotubes in the field of view. (M) The number of nuclei per myotube. (N) The myotube diameter. To reflect the myotube diameter as accurately as possible, the vertical line at the thinnest position of the myotube is taken as the minimum measured (Min), the mid-perpendicular line of the long myotube axis is taken as the middle measured (Middle), and the vertical line at the widest position of the myotube is taken as the maximum measured (Max).

Although the mRNA levels of MyoD1 and MyoG were significantly increased after induced differentiation 2 days in MF^{+/-} cells (Figure 3G), the mRNA level of MyHC (Figure 3G) and the protein levels of MyoD1, MyoG, and MyHC (Figure 3H, I) were dramatically decreased ($P < 0.05$), suggesting that the MSTN^{Del273C} mutation with FGF5 inhibit myogenic differentiation. Meanwhile, the immunofluorescence staining of MyoG and MyHC in myotubes showed that myotube fusion index (Figure 3J, K), number of myotubes (Figure 3J, L), and number of nuclei per myotube (Figure 3J, M) were all highly significantly ($P < 0.01$) reduced after inducing differentiation for 2 days of MF^{+/-} cells compared to WT cells, as was

the myotube diameter at the maximum measured (Figure 3J, N). To continue follow-up tracing of the progression of myogenic differentiation, we also performed MyoG and MyHC immunofluorescence staining after inducing differentiation for 4 days (DM4) and 6 days (DM6), and the results showed that the differentiation capacity and fusion ability of MF^{+/-} cells were consistently significantly lower than WT cells during the ongoing differentiation process, as was the diameter of fused myotubes (Figure S4A-J). The reduced expression of myogenic differentiation markers further confirmed that the *MSTN*^{Del273C} mutation with *FGF5* knockout consistently inhibits myogenic differentiation of skeletal muscle satellite cells (Figure S4K-N). Taken together, our results elucidated that the *MSTN*^{Del273C} mutation with *FGF5* knockout inhibits myogenic differentiation of skeletal muscle satellite cells and induces a smaller myotube diameter of myotubes after induced differentiation, which may explain why the cross-sectional area of muscle fibers is decreased in MF^{-/-} and MF^{+/-} sheep.

3.4 FOSL1 is a key gatekeeper of *MSTN*^{Del273C} mutation with *FGF5* knockout-mediated muscle phenotype

To elucidate the potential mechanism of the *MSTN*^{Del273C} mutation with *FGF5* knockout result in smaller muscle fiber cross-sectional area and myotube diameter, the RNA-seq was performed in gluteus medius. A total of 25,958 genes were identified by RNA-seq, and principal component analysis (PCA) showed relatively well repeatability within sample groups and well discrimination between WT and MF^{+/-} samples (Figure 4A). With *P*-value < 0.05 and | log2 Fold Change | > 1 as the screening criterion, 295 differentially expressed genes (DEGs) were screened, including 79 up-regulated DEGs and 216 down-regulated DEGs (Figure 4B). The cluster analysis showed that the samples were clustered into WT groups and MF^{+/-} groups, with obvious differences between groups (Figure 4C). Pearson correlation analysis also showed high similarity within sample groups (Figure 4D).




Figure 4

Identification of potential regulators by RNA-seq

(A) Principal component analysis (PCA) of six gluteus medius samples in WT and MF^{+/-} sheep. (B) Volcano plot of differentially expressed genes (DEGs) between WT and MF^{+/-} sheep. The up- and down-regulated DEGs are shown in red and blue, respectively. (C) The heat map of DEGs between WT and MF^{+/-} sheep. (D) Pearson correlation analysis between samples. (E) Go enrichment analysis of DEGs. Among them, the top 20 entries with significant enrichment are listed in biological process (BP). CC, cellular component; MF, molecular function. (F) KEGG enrichment analysis of DEGs. (G) The expression verification of DEGs by RT-qPCR.

GO enrichment analysis showed that 295 DEGs were significantly enriched in signal transduction, positive regulation of cell proliferation, positive regulation of cell migration, skeletal muscle cell differentiation, muscle contraction, cardiac muscle contraction, and positive regulation of JNK cascade and so on in biological process (BP); in cellular component (CC), these DEGs mainly belonged to cell membrane, cytoplasm, perinuclear region of cytoplasm, and I band; and molecular function (MF) mainly included protein binding, nucleotide binding, ATP binding, and protein kinase activity (Figure 4E), indicating that these DEGs are significantly closely related to cell proliferation, myogenic differentiation, and muscle development. In addition, KEGG enrichment analysis showed that 295 DEGs were significantly enriched in cytokine-cytokine receptor interaction, MAPK signaling pathway, IL-17 signaling pathway, and TNF signaling pathway (Figure 4F), implying that DEGs were significantly associated with cell proliferation, differentiation, apoptosis, and inflammation. Furthermore, based on GO and KEGG enrichment analysis, 18 genes with a large difference were selected from 295 DEGs for validation at mRNA level in gluteus medius. The results showed that *GLIS1* was significantly ($P < 0.05$) up-regulated, and *MYL10*, *FOSL1*, *PDPN*, *PLA1A*, and *ANKRD2* were significantly ($P < 0.05$) down-regulated (Figure 4G).

In addition, we also verified the above six DEGs in the longissimus dorsi, in which *FOSL1*, *PDPN* and *ANKRD2* were significantly ($P < 0.05$) reduced in MF^{+/-} sheep (Figure S5A). Given that *MSTN*^{Del273C} mutation with *FGF5* knockout promotes skeletal muscle satellite cell proliferation and inhibits differentiation, we dynamically monitored the expression of

FOSL1, *PDPN*, and *ANKRD2* during myogenic differentiation. The results indicated that both *PDPN* and *ANKRD2* were significantly ($P<0.05$) up-regulated during myogenic differentiation (Figure 5B-C). More strikingly, *FOSL1* mRNA level was strongly ($P<0.01$) decreased after induced differentiation (Figure 5A), and its expression diminished continuously with the differentiation progress. Furthermore, compared with WT cells, the mRNA expression levels of *FOSL1* in $MF^{+/-}$ cells at GM and DM2 were significantly ($P<0.05$) elevated (Figure 5B), suggesting that *FOSL1* may play a crucial role in the proliferation and myogenic differentiation of skeletal muscle satellite cells.




Figure 5

FOSL1 may regulate myogenesis by binding to the MyoD1 promoter region

(A) The expression level of *FOSL1* mRNA during myogenic differentiation. (B) The mRNA expression levels of *FOSL1* both at GM and DM2 in WT and $MF^{+/-}$ cells. (C) The protein-protein interaction (PPI) analysis of *FOSL1*, *c-Fos* and *MyoD1*. (D) The mRNA expression level of *c-Fos* and *MyoD1* at GM in WT and $MF^{+/-}$ myoblasts. (E) Schematic diagram of *MyoD1* gene body, promoter region and binding sites. (F-G) *FOSL1* recognition motif in the *MyoD1* promoter region. (H) *FOSL1* ChIP-qPCR of motif 1 recognition region. (I) *FOSL1* ChIP-qPCR of motif 2 recognition region.

As aforementioned above, the AP-1 transcription factor family member *c-Fos* inhibits myogenesis and *MyoD1* expression by directly binding to the *MyoD1* promoter region. Given that *FOSL1* is a member of the AP-1 family, we, therefore, speculated that *FOSL1* might have similar functions to *c-Fos*. Subsequent protein-protein interaction (PPI) analysis of *FOSL1*, *c-Fos* and *MyoD1* further suggested that there was a potential interaction between *FOSL1* and *MyoD1* (Figure 5C). In addition, we also found that the mRNA expression level of *c-Fos* was highly significantly ($P<0.01$) reduced in $MF^{+/-}$ myoblasts compared with WT cells, whereas the expression level of *MyoD1* mRNA was dramatically ($P<0.01$) increased (Figure 5D). Given the physical interaction between *c-Fos* and *MyoD1*, the JASPAR database (<https://jaspar.genereg.net/>) was used to predict the binding of *FOSL1* to *MyoD1* promoter region, and found that two bZIP recognition sites in the *MyoD1* promoter region had the most significant binding potential to *FOSL1*, of which motif 1 located in the -1839 to -1830 region and motif 2 was located in the -1273 to -1264 region (Figure 5E-G). Subsequently, ChIP-qPCR confirmed that *FOSL1* directly binds to these two bZIP recognition sites in the *MyoD1* promoter region (Figure 5H-I), indicating that *FOSL1* plays an important role in the transcriptional regulation of *MyoD1*.

3.5 The *MSTN*^{Del273C} mutation with *FGF5* knockout contribute to muscle phenotype via MEK-ERK-FOSL1 axis

As previously mentioned, *FOSL1* may be a key gatekeeper of *MSTN*^{Del273C} mutation with *FGF5* knockout-mediated muscle phenotype. Given that, we also investigated the protein levels of *FOSL1* and c-Fos in GM and MD2, respectively. The results showed that the protein level of *FOSL1* was significantly ($P < 0.05$) reduced and c-Fos protein levels were significantly ($P < 0.05$) decreased in MF^{+/-} cells at GM compared with WT cells (Figure 6A-B), whereas *FOSL1* protein levels were significantly ($P < 0.05$) diminished and c-Fos protein levels were highly significantly ($P < 0.01$) elevated in MF^{+/-} cells after induced differentiation (Figure 6F-G), which further demonstrated the key role of *FOSL1* on myogenesis. As demonstrated previously, enrichment analysis significantly enriched the MAPK signaling pathway. Compared with WT cells, the p-*FOSL1* protein level of MF^{+/-} cells was strongly increased at GM ($P < 0.01$) (Figure 6A-B), and there was no significant ($P > 0.05$) difference between MEK1/2 and p-MEK1/2 protein levels (Figure 6A, C), but its downstream ERK1/2 protein level was extremely significantly ($P < 0.01$) decreased, and accompanied by a significant ($P < 0.05$) increase in p-ERK1/2 protein levels (Figure 6A, D). In addition, there was no significant ($P > 0.05$) difference in p38 MAPK protein level, but p-p38 MAPK protein level was significantly ($P < 0.05$) enhanced (Figure 6A, E). After induced differentiation, there was no significant ($P > 0.05$) difference in p-*FOSL1* protein level in MF^{+/-} cells compared with WT cells (Figure 6F-G), although both MEK1/2 and ERK1/2 protein levels were dramatically ($P < 0.01$) inhibited, there was no significant ($P > 0.05$) difference in their phosphorylated protein levels (Figure 6F, H-I). In addition, with a strong ($P < 0.01$) decrease in the p38 MAPK protein level, the p-p38 MAPK protein level dramatically ($P < 0.01$) increased (Figure 6F, J). These results suggested that *MSTN*^{Del273C} mutation with *FGF5* knockout may regulate the expression and activity of *FOSL1* via the MEK1/2-ERK1/2-FOSL1 axis to affect the proliferation and myogenic differentiation of skeletal muscle satellite cells.




Figure 6

The *MSTN*^{Del273C} mutation with *FGF5* knockout contributes to muscle phenotype via MEK-ERK-FOSL1 axis

(A) Western blot of *FOSL1*, c-Fos, and key kinases of MAPK signaling pathways in GM. (B-E) Quantification of protein expression of *FOSL1*, c-Fos, and key kinases of MAPK signaling pathways in GM. (F) Western blot of *FOSL1*, c-Fos, and key kinases of MAPK signaling pathways in DM2. (G-J) Quantification of protein expression of *FOSL1*, c-Fos, and key kinases of MAPK signaling pathways in DM2.

To investigate the role of *FOSL1* on the proliferation and myogenic differentiation of skeletal muscle satellite cells, we successfully constructed *FOSL1* gain-of-function model (Figure 7A, G-H). Our results showed that overexpression of *FOSL1* significantly ($P<0.01$) increased the cell proliferation rate (Figure 7B), and the mRNA expression levels of cell proliferation-related marker genes also significantly ($P<0.05$) increased (Figure 7C). Meanwhile, the EdU cell proliferation assay further demonstrated the promoting effect of *FOSL1* overexpression on cell proliferation (Figure 7D-E). Similarly, we also investigated the expression of c-Fos and MyoD1, respectively. As anticipated, the overexpression of *FOSL1* inhibited the MyoD1 mRNA ($P<0.01$) and protein ($P<0.05$) expression levels (Figure 7F, G-H), and significantly ($P<0.05$) suppressed mRNA expression level of c-Fos (Figure 7F), and we also observed a significant ($P<0.01$) increase in the expression level of p-FOSL1 protein (Figure 7G-H). These results are consistent with what we observed in MF^{+/-} cells at GM, suggesting a potential inhibitory effect of p-FOSL1 protein levels on MyoD1.




Figure 7

FOSL1 overexpression promotes the proliferation of skeletal muscle satellite cells

(A) The mRNA expression level of FOSL1 at GM and DM2 after lentivirus infection. (B) The number of cells detected by CCK-8 at 0h, 12h, 24h, 36h, 48h, and 60h after infection with lentivirus. (C) The mRNA expression levels of cell cycle marker genes and cell proliferation marker genes. (D-E) EdU assay showed that the number of EdU positive cells and EdU labeling index were significantly increased after infection with lentivirus. Scale bar 130 μ m. (F) The mRNA expression levels of c-Fos and MyoD1 at GM after FOSL1 overexpression. (G-H) The protein expression levels of FOSL1, p-FOSL1 and MyoD1 at GM after FOSL1 overexpression.

pression. (G-H) The protein expression levels of FOSL1, p-FOSL1 and MyoD1 at GM after FOSL1 overexpression.

In addition, we also investigated the effect of *FOSL1* over-expression on cell differentiation. Although the mRNA expression level of MyoG was significantly increased ($P<0.01$) with an up-regulated tendency on MyoD1 mRNA, the expression level of MyHC mRNA was significantly ($P<0.05$) reduced after FOSL1 overexpression (Figure 8A). More importantly, the protein expression levels of MyoD1, MyoG and MyHC were all significantly decreased ($P<0.05$), proving that the overexpression of FOSL1 inhibited the myogenic differentiation of skeletal muscle satellite cells. Meanwhile, the p-FOSL1 protein expression level was also significantly ($P<0.01$) elevated with the increase of FOSL1 protein expression level (Figure 8B-C). Subsequently, immunofluorescence staining further confirmed the significant ($P<0.05$) inhibitory effect of *FOSL1* overexpression on cell differentiation (Figure 8D-E). Also, the number of myotubes, the number of nuclei per myotube, and the myotube diameter all significantly decreased ($P<0.05$) (Figure 8D, F-H). These results further demonstrated that

elevated p-FOSL1 protein level inhibits myogenic differentiation and produces smaller myotubes.




Figure 8

Highly expressed or activated FOSL1 inhibits myogenic differentiation

(A) The mRNA expression levels of myogenic differentiation marker genes MyoD1, MyoG and MyHC at DM2 after overexpression of FOSL1. (B-C) The protein expression levels of FOSL1, p-FOSL1 and myogenic differentiation marker genes MyoD1, MyoG and MyHC at DM2 after overexpression of FOSL1. (D) The MyoG and MyHC immunofluorescence staining of myotubes at DM2 after overexpression of FOSL1. Scale bar 130 μm. (E-H) The myotube fusion index, number of myotubes, number of nuclei per myotube and the myotube diameter at DM2 after overexpression of FOSL1. (I) The MyoG and MyHC immunofluorescence staining of myotubes at DM2 after addition of 20 μM TBHQ. Scale bar 130 μm. (J-M) The myotube fusion index, number of myotubes, number of nuclei per myotube and the myotube diameter at DM2 after the addition of 20 μM TBHQ.

To further ascertain this insight, the tert-butylhydroquinone (TBHQ), which can strongly activate ERK1/2 and increase p-ERK1/2 protein expression level, was used to activate ERK1/2 and act as an indirect activator of FOSL1. As expected, the addition of 20 μM TBHQ significantly ($P < 0.01$) inhibited the myogenic differentiation of skeletal muscle satellite cells (Figure 8I-J). And, the number of myotubes was significantly increased ($P < 0.05$) (Figure 8I, K), while the number of nuclei per myotube was significantly ($P < 0.05$) decreased and produced a smaller myotube diameter ($P < 0.05$) (Figure 8I, L-M). Taken together, these results repeatedly confirm that FOSL1 as a key gatekeeper of MSTN^{Del273C} mutation with FGF5 knockout-mediated muscle phenotype.

In short, our results shed light that the MSTN^{Del273C} mutation with FGF5 knockout mediated the activation of FOSL1 via MEK-ERK-FOSL1 axis, further promotes skeletal muscle satellite cell proliferation, and inhibits myogenic differentiation by inhibiting the transcription of

MyoD1, and resulting in smaller myotubes (Figure 9). Our results demonstrate the potential mechanism for smaller muscle fibers of *MSTN*^{Del273C} mutation with *FGF5* knockout sheep.




Figure 9

Schematic illustration of the regulation of muscle phenotypes by *MSTN*^{Del273C} mutation with *FGF5* knockout

The *MSTN*^{Del273C} mutation with *FGF5* knockout mediated the activation of FOSL1 via MEK-ERK-FOSL1 axis. The activated FOSL1 further promotes skeletal muscle satellite cell proliferation and inhibits myogenic differentiation, and resulting in smaller myotubes, which demonstrates the potential mechanism for smaller muscle fibers of *MSTN*^{Del273C} mutation with *FGF5* knockout sheep.

4 Discussion

4.1 Optimized Cas9 mRNA and sgRNA delivery ratio improves the efficiency of dual-gene biallelic homozygous mutations

The strategy for producing gene knockout animals by CRISPR/Cas9 gene editing system is usually to introduce the Cas9 mRNA and the sgRNA of the target gene into their prokaryotic embryos by microinjection. However, this “one-step” method often results in a “mosaic” of gene-edited offspring, that is, due to the fertilized egg will divide into multiple blastomeres successively many times, the editing ability and editing mode of the CRISPR/Cas9 system for each blastomere may be different, thereby resulting in the occurrence of chimeric mutant individuals carrying both the wild-type and mutant alleles (Wan *et al.*, 2015). Such chimeric mutants have now been reported in gene knockout mice (Wang *et al.*, 2013), rats (Bao *et al.*, 2015), monkeys (Niu *et al.*, 2014), pigs (Hai *et al.*, 2014), sheep (Hongbing HAN, 2014), goats (Wang *et al.*, 2015), rabbits (Lv *et al.*, 2016), and humans (Wang and Yang, 2019) prepared by a “one-step” method using the CRISPR/Cas9 system. For studies involved in genetic phenotypes, chimeric gene knockout animals require further cross-breeding to obtain animals with a complete knockout of the target gene. Once required to generate multiple gene knockout animals, this time-consuming and laborious operation will become extremely difficult. Although many studies have been devoted to eliminating this widespread chimeric mutation (Sato *et al.*, 2015; Sung *et al.*, 2014; Kotani *et al.*, 2015; Chen *et al.*, 2015; Zhou *et al.*, 2014; Tu *et al.*, 2017; Wang *et al.*, 2015), however, these optimizations did not bring about a significant improvement in the production efficiency of biallelic knockout animals. Here, we

increased the delivery ratio of Cas9 mRNA to sgRNA from 1:2 to 1:10, which improve the efficiency of the homozygous mutation of the biallelic gene. This unprecedented optimization method not only improved the overall gene knockout efficiency, but also the obtained gene-edited offspring were all dual-gene biallelic mutation.

4.2 Phenotypes produced by *MSTN* mutations are mutation site-dependent

As mentioned previously, although *MSTN* mutations have been found to produce a “double-muscle” phenotype in multiple species, the microscopic phenotypes are different, and this difference is closely related to the mutation site and species types. In mice, the number of skeletal muscle fibers with *MSTN* gene knockout significantly increased by 86% (McPherron *et al.*, 1997). A missense mutant *MSTN* only increased the number of mouse muscle fibers, while dominant negative *MSTN* resulted in increased muscle fiber cross-sectional area in mice, but not the number of muscle fibers (Nishi *et al.*, 2002; Zhu *et al.*, 2000). In addition, the use of *MSTN* neutralizing antibody on adult rats also resulted in an increased muscle fiber cross-sectional area (Haidet *et al.*, 2008). In cattle, natural *MSTN* mutant Belgian Blue cattle had an increased number of muscle fibers and reduced muscle fiber diameter (Wegner *et al.*, 2000). The muscle fiber cross-sectional area of longissimus dorsi and gluteus medius in sheep was significantly increased after a 4bp deletion of the first exon of *MSTN* (Zhiliang *et al.*, 2004). In pigs, both the *MSTN* gene-edited Meishan and Hubei pigs showed a phenotype with increased muscle fiber density (Qian *et al.*, 2015; Xu *et al.*, 2013). Here, we prepared *MSTN*^{Del273C} mutation with *FGF5* knockout sheep with 3-base pairs of AGC in the third exon of *MSTN*, which caused the deletion of cysteine at amino acid position 273. Its macroscopic phenotype is similar to that of the *MSTN*-edited sheep with the first exon knocked out 4-base pairs. Both of them showed an abnormally developed “double-muscle” phenotype of hip muscle, but the microscopic phenotype was exactly the opposite.

4.3 The phenotype of *MSTN*^{Del273C} mutation with *FGF5* knockout sheep is only controlled by *MSTN*

Although we produced the *MSTN*^{Del273C} mutation with *FGF5* knockout sheep, *FGF5* is currently recognized to be an important regulator of hair growth and development and there is no direct evidence of a potential regulatory role of *FGF5* on muscle development (Xu *et al.*, 2020; Zhang *et al.*, 2020; Higgins *et al.*, 2014; Hebert *et al.*, 1994). Furthermore, there is no evidence of the crosstalk between *MSTN* and *FGF5*. Importantly, we also did not find a significant effect on muscle fiber phenotype in muscle morphological analysis of *FGF5* knockout alone sheep. These evidence support whether it is homozygous mutant F0 generation or heterozygous mutant F1 generation, the reduction of muscle fiber cross-sectional area of *MSTN*^{Del273C} mutation with *FGF5* knockout sheep is only controlled by *MSTN*, whereas not *FGF5*. These results indicate that *MSTN* may control skeletal muscle weight from two relatively independent aspects regulating the number of muscle fibers during embryonic development and the muscle fiber size after birth.

4.4 The *MSTN*^{Del273C} mutation with *FGF5* knockout activate *FOSL1* and promote cell proliferation

The proliferation and differentiation of skeletal muscle satellite cells is a key step in myogenesis and muscle development, which is a highly coordinated multistep biological process driven by many myogenic regulatory factors such as paired box families (Pax3/7), myogenic regulatory factors (Myogenin, MyoD, Myf5, and MRF4/6), myocyte enhancer factor

2 (MEF2) family proteins, these factors collectively regulate the expression of muscle specific genes and to control skeletal muscle development (Braun and Gautel, 2011). Aside from myogenic regulatory factor, MSTN has been repeatedly demonstrated to be involved in the proliferation (Thomas *et al.*, 2000b; Taylor *et al.*, 2001; Huang *et al.*, 2007; Ge *et al.*, 2020) and differentiation (Langley *et al.*, 2002; Gao *et al.*, 2020) of skeletal muscle satellite cells. MSTN negatively regulates the G1/S phase transition of cell cycle by specifically up-regulating cyclin dependent kinase inhibitors p21WAF1/CIP1, and reducing the level and activity of Cyclin-dependent kinase 2 (CDK2) protein in myoblasts (Thomas *et al.*, 2000a; Joulia *et al.*, 2003; McCroskery *et al.*, 2003), resulting in the arrest of myoblasts in G1 phase of cell cycle, so as to maintain the static state of satellite cells. In this study, the *MSTN*^{Del273C} mutation with *FGF5* knockout promoted the transformation of G1/S phase by reducing the proportion of cell cycle G1 phase and increasing the proportion of S phase, resulting in the activation of skeletal muscle satellite cells and entry into the cell cycle, and further promoting cell proliferation. Furthermore, *FOSL1* has been repeatedly proved to promote the proliferation of a variety of cells, especially tumor cells (Sobolev *et al.*, 2022; Talotta *et al.*, 2020). In the current study, the *MSTN*^{Del273C} mutation with *FGF5* knockout led to the increase of p-FOSL1 level, and the over-expression of *FOSL1* also promoted cell proliferation, suggesting that the activated *FOSL1* is a key factor in the proliferation of skeletal muscle satellite cells. Altogether, our results support that the *MSTN*^{Del273C} mutation with *FGF5* knockout promotes the proliferation of skeletal muscle satellite cells by activating *FOSL1*.

4.5 FOSL1 binds to the MyoD1 promoter and inhibits its transcription

In this study, AP-1 family member *FOSL1* was significantly reduced in MF^{+/-} sheep, and its expression were drastically reduced during myogenic differentiation, which was consistent with the decrease of *FOSL1* expression during C2C12 differentiation (Tobin *et al.*, 2016). Therefore, *FOSL1* was recognized as a potential gatekeeper. As mentioned previously, c-Fos, a member of the AP-1 transcription factor family, has been shown to inhibit myogenesis and MyoD1 expression by directly binding to the MyoD1 promoter region (Li *et al.*, 1992). Moreover, *FOSL1* heterodimerizes with other transcription factors, such as the members of the bZIP family, and these dimers are either disabling the transcriptional activator complex or saving the interacting proteins from degradation in proteasomes (Sobolev *et al.*, 2022). Therefore, we speculate that *FOSL1* may have similar functions to c-Fos. PPI analysis of *FOSL1*, c-Fos and MyoD1 suggested a potential interaction between *FOSL1* and MyoD1. Subsequently, we confirmed that *FOSL1* directly binds to two bZIP recognition sites in the MyoD1 promoter region. Meanwhile, the overexpression of *FOSL1* confirmed the potential inhibitory effect of *FOSL1* and p-FOSL1 on MyoD1. In addition, *FOSL2*, another AP-1 family member, can also inhibit myoblast differentiation (Alli *et al.*, 2013), which may support the inhibitory effect of *FOSL1* on myogenic differentiation. In a word, these results fully support our hypothesis that *FOSL1* binds the MyoD1 promoter and inhibits its transcription.

4.6 The *MSTN*^{Del273C} mutation with *FGF5* knockout contribute to muscle phenotype via MEK-ERK-FOSL1 axis

MSTN dimer first binds to ActRIIB, and then binds to ALK4/5 to form a complex. Smad2/3/4 enters the nucleus to regulate the expression of target genes, and different transcription factors bind to Smad2/3/4 complex, resulting in different functions of Smad signaling pathway (Chen *et al.*, 2021b). The nonclassical pathway of MSTN involves PI3K/Akt/mTOR signaling pathway and MAPK signaling pathway, which mainly includes ERKs, JNKs and p38 MAPK (Huang *et al.*, 2007; Gui *et al.*, 2012). All of those pathways are involved in the signal transduction pathway of MSTN and mediate the transcription of MRFs (Myogenin, Myf5,

MyoD), MuRF-1 and Atrogin-1, to regulate myogenic differentiation and skeletal muscle quality (Chen *et al.*, 2021b).

MSTN induces muscle fiber hypertrophy prior to satellite cell activation (Wang and McPherron, 2012) and inhibits IGF-I-induced increase in myotube diameter through Akt signaling pathway (Morissette *et al.*, 2009). Recently, a study on the downstream target gene *Smad2* of *MSTN* showed that the knock-out of *Smad2* expression in primary myoblasts did not affect the efficiency of myogenic differentiation, but produced smaller myotubes with reduced expression of the terminal differentiation marker myogenin. In turn, the overexpression of *Smad2* stimulated the expression of myogenin and enhanced cell differentiation and fusion (Lamarche *et al.*, 2021). In our study, the *MSTN*^{Del273C} mutation with *FGF5* knockout resulted in the inhibition of myogenic differentiation of skeletal muscle satellite cells, and the number of myotubes and the myotube size were significantly reduced.

As previously described, the DEGs of gluteus medius RNA-seq were significantly enriched in the MAPK signaling pathway. A recent study on glioma showed that *FOSL1* can be activated by the Ras-MEK1/2-ERK1/2 axis in MAPK signaling pathway (Marques *et al.*, 2021). Similarly, the activated MEK1/2-ERK1/2 axis in aged skeletal muscle also activates *FOSL1* and increases the abundance of *FOSL1* and the trans-activation capacity of the Fos-Jun heterodimer (Mathes *et al.*, 2021). In our study, the *MSTN*^{Del273C} mutation with *FGF5* knockout regulates *FOSL1* expression and activity through MEK1/2-ERK1/2-*FOSL1* axis and activated *FOSL1* further inhibits myogenic differentiation of skeletal muscle satellite cells, resulting in smaller myotube diameter. However, puzzlingly, despite the high expression of p-*FOSL1* in MF^{+/-} myoblasts, it did not significantly inhibit the transcription of *MyoD1*, which may be related to a dramatic enhance in c-Fos, or there might be other signaling pathways regulating *MyoD1* after *MSTN*^{Del273C} mutation with *FGF5* knockout. Furthermore, it has been demonstrated that the inhibition of MEK1/2 using MEK1/2-specific inhibitor PD184352 can significantly down-regulate *FOSL1* expression (Mathes *et al.*, 2021). To further confirm our hypothesis, TBHQ was used to activate ERK1/2 and act as an indirect activator of *FOSL1*. Interestingly, activated *FOSL1* markedly inhibited myogenic differentiation of skeletal muscle satellite cells, which also resulted in smaller myotubes, but significantly increased the number of myotubes. Taken together, these results shed light on the potential mechanisms by which *MSTN*^{Del273C} mutation with *FGF5* knockout leads to increased myofiber numbers and decreased fiber cross-sectional area.

5 Conclusion

In this study, we found that increasing the delivery ratio of Cas9 mRNA to sgRNA can improve the efficiency of the homozygous mutation of the biallelic gene. Based on this, we generated a *MSTN*^{Del273C} mutation with *FGF5* knockout sheep, a dual-gene biallelic homozygous mutant, which highlights a dominant “double-muscle” phenotype. Both F0 and F1 generation mutants highlight the excellent trait of high-yield meat and the more number of muscle fibers per unit area. Our results suggested the *MSTN*^{Del273C} mutation with *FGF5* knockout mediated the activation of *FOSL1* via MEK-ERK-*FOSL1* axis, further promotes skeletal muscle satellite cell proliferation, and inhibits myogenic differentiation by inhibiting the transcription of *MyoD1*, and resulting in smaller myotubes. This supports the myofiber hyperplasia that more number of muscle fibers and smaller cross sectional area, caused by the *MSTN*^{Del273C} mutation with *FGF5* knockout.

Data availability statement

The raw sequence data reported in this paper have been deposited in the Genome Sequence Archive (Genomics, Proteomics & Bioinformatics 2021) in National Genomics Data Center (Nucleic Acids Res 2022), China National Center for Bioinformation / Beijing Institute of Genomics, Chinese Academy of Sciences (GSA: CRA008539) that are publicly accessible at <https://ngdc.cncb.ac.cn/gsa>.

Ethics statement

All experiments were performed in accordance with relevant guidelines and adhere to the ARRIVE guidelines (<https://arriveguidelines.org/>) for the reporting of animal experiments. All sheep are raised in accordance with the national feeding standard NT/T815-2004. All procedures performed were consistent with the National Research Council Guide for the Care and Use of Laboratory Animals. All experimental animal protocols were approved and performed in accordance with the requirements of the Animal Care and Use Committee at China Agricultural University (AW02012202-1-3).

Competing financial interests

The authors declare that there are no competing financial interests.

Author contributions

MMC performed the majority of experiments, data analysis, and drafted the manuscript. YZ performed a part of experiments and revised the manuscript. XLX, SJW and ZML helped with data analysis. XSZ, JLZ and XFG were responsible for the management of the feeding plant, slaughtering, and collecting samples. YMY helped to process some biological information data. SYQ, GY, SQW, HXL and AWW helped to collect and organize original data. GSL led the prokaryotic injection and embryo transfer. YL prepared the gene editing sheep. KY and HBH participated in project management. KY, FHL and ZXI conceived the project, revised manuscript and final approval of manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by National Key Research and Development Program-Key Projects (2021YFF1000704, 2021YFD1200900), Natural Science Foundation of China (32072722), and National Transgenic Creature Breeding Grand Project (2016zx08008-003).

Figure Legends




Figure S1

FGF5 mutation does not affect muscle fiber size

(A) HE sections of gluteus medius in WT and *FGF5*^{+/-} sheep. Scale bar 100 μ m. (B) Quantification of muscle fibre cell area of gluteus medius in WT and *FGF5*^{+/-} sheep. (C) Quantification of muscle fibre cell number of per unit area in WT and *FGF5*^{+/-} sheep. (D) The percentage of cross-sectional area of different size muscle fibers




Figure S2

Genotype identification of F1 generation MF^{+/-} sheep

(A) Identification of *MSTN* mutation type. The ear, liver, skin and muscle tissues of F1 generation MF^{+/-} sheep were selected to identify the genotype of *MSTN*. (B) *MSTN* mutation sequencing peak. (C) Identification of *FGF5* mutation type. The ear tissue of F1 generation MF^{+/-} sheep was selected to identify the genotype of *FGF5*. (D-E) *FGF5* mutation sequencing peak.




Figure S3

The *MSTN*^{Del273C} mutation with *FGF5* knockout has no potential effect on *MSTN* expression

(A) *MSTN* immunohistochemistry of gluteus medius and longissimus dorsi in WT and MF^{-/-} sheep. (B) *MSTN* mRNA expression level of gluteus medius in WT and MF^{+/-} sheep. (C-D) *MSTN* protein expression level of gluteus medius in WT and MF^{+/-} sheep. (E) *MSTN* immunofluorescence staining in myoblasts and myotubes of WT and MF^{+/-} sheep.




Figure S4

The myogenic differentiation ability of MF^{+/-} cells was continuously inhibited

(A) The MyoG and MyHC immunofluorescence staining of myotubes in DM4. Scale bar 130 μm. (B-E) The myotube fusion index, number of myotubes, number of nuclei per myotube and the myotube diameter in DM4. (F) The MyoG and MyHC immunofluorescence staining of myotubes in DM6. Scale bar 130 μm. (G-J) The myotube fusion index, number of myotubes, number of nuclei per myotube and the myotube diameter in DM6. (K) The protein expression levels of myogenic differentiation marker genes and potential regulator FOSL1 and its family member c-Fos during myogenic differentiation. (L-N) Quantification of protein levels of myogenic differentiation marker genes.




Figure S5

The expression of DEGs at different levels

(A) The expression level of DEGs in the longissimus dorsi. (B) The expression level of PDPN mRNA during myogenic differentiation. (C) The expression level of ANKRD2 mRNA during myogenic differentiation.

References

- Alli N. S. , Yang E. C. , Miyake T. , Aziz A. , Collins-Hooper H. , Patel K. , McDermott J. C (2013) **Signal-dependent fra-2 regulation in skeletal muscle reserve and satellite cells** *Cell Death Dis* **4**
- Baig M. H. , Ahmad K. , Moon J. S. , Park S. Y. , Ho Lim J. , Chun H. J. , Qadri A. F. , Hwang Y. C. , Jan A. T. , Ahmad S. S. , Ali S. , Shaikh S. , Lee E. J. , Choi I (2022) **Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies** *Front Physiol* **13**
- Bao D. , Ma Y. , Zhang X. , Guan F. , Chen W. , Gao K. , Qin C. , Zhang L (2015) **Preliminary Characterization of a Leptin Receptor Knockout Rat Created by CRISPR/Cas9 System** *Sci Rep* **5**
- Bengal E. , Ransone L. , Scharfmann R. , Dwarki V. J. , Tapscott S. J. , Weintraub H. , Verma I. M (1992) **Functional antagonism between c-Jun and MyoD proteins: a direct physical association** *Cell* **68**:507–519
- Boman I. A. , Klemetsdal G. , Blichfeldt T. , Nafstad O. , Vage D. I (2009) **A frameshift mutation in the coding region of the myostatin gene (MSTN) affects carcass conformation and fatness in Norwegian White Sheep (Ovis aries)** *Anim Genet* **40**:418–422
- Boman I. A. , Vage D. I (2009) **An insertion in the coding region of the myostatin (MSTN) gene affects carcass conformation and fatness in the Norwegian Spaelsau (Ovis aries)** *BMC Res Notes* **2**
- Braun T. , Gautel M (2011) **Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis** *Nat Rev Mol Cell Biol* **12**:349–361

Chen M. , Zhang L. , Guo Y. , Liu X. , Song Y. , Li X. , Ding X. , Guo H. (2021) **A novel lncRNA promotes myogenesis of bovine skeletal muscle satellite cells via PFN1-RhoA/Rac1** *J Cell Mol Med*

Chen M. M. , Zhao Y. P. , Zhao Y. , Deng S. L. , Yu K (2021) **Regulation of Myostatin on the Growth and Development of Skeletal Muscle** *Front Cell Dev Biol* 9

Chen Y. , Zheng Y. , Kang Y. , Yang W. , Niu Y. , Guo X. , Tu Z. , Si C. , Wang H. , Xing R. , Pu X. , Yang S. H. , Li S. , Ji W. , Li X. J (2015) **Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9** *Hum Mol Genet* 24:3764–3774

Dehnavi E. , Ahani Azari M. , Hasani S. , Nassiry M. R. , Mohajer M. , Khan Ahmadi A. , Shahmohamadi L. , Yousefi S (2012) **Polymorphism of Myostatin Gene in Intron 1 and 2 and Exon 3, and Their Associations with Yearling Weight, Using PCR-RFLP and PCR-SSCP Techniques in Zel Sheep** *Biotechnol Res Int* 2012

Dierks C. , Momke S. , Philipp U. , Distl O (2013) **Allelic heterogeneity of FGF5 mutations causes the long-hair phenotype in dogs** *Anim Genet* 44:425–431

Dilger A. C. , Gabriel S. R. , Kutzler L. W. , McKeith F. K. , Killefer J (2010) **The myostatin null mutation and clenbuterol administration elicit additive effects in mice** *Animal* 4:466–471

Fan Z. , Liu Z. , Xu K. , Wu T. , Ruan J. , Zheng X. , Bao S. , Mu Y. , Sonstegard T. , Li K (2022) **Long-term, multidomain analyses to identify the breed and allelic effects in MSTN-edited pigs to overcome lameness and sustainably improve nutritional meat production** *Sci China Life Sci* 65:362–375

Gao L. , Yang M. , Wei Z. , Gu M. , Yang L. , Bai C. , Wu Y. , Li G (2020) **MSTN Mutant Promotes Myogenic Differentiation by Increasing Demethylase TET1 Expression via the SMAD2/SMAD3 Pathway** *Int J Biol Sci* 16:1324–1334

Ge L. , Dong X. , Gong X. , Kang J. , Zhang Y. , Quan F (2020) **Mutation in myostatin 3'UTR promotes C2C12 myoblast proliferation and differentiation by blocking the translation of MSTN** *Int J Biol Macromol* 154:634–643

Grisolia A. B. , D'Angelo G. T. , Porto Neto L. R. , Siqueira F. , Garcia J. F (2009) **Myostatin (GDF8) single nucleotide polymorphisms in Nelore cattle** *Genet Mol Res* 8:822–830

Grobet L. , Martin L. J. , Poncelet D. , Pirottin D. , Brouwers B. , Riquet J. , Schoeberlein A. , Dunner S. , Menissier F. , Massabanda J. , Fries R. , Hanset R. , Georges M (1997) **A deletion in the bovine myostatin gene causes the double-musled phenotype in cattle** *Nat Genet* 17:71–74

Gui T. , Sun Y. , Shimokado A. , Muragaki Y (2012) **The Roles of Mitogen-Activated Protein Kinase Pathways in TGF-beta-Induced Epithelial-Mesenchymal Transition** *J Signal Transduct* 2012

Hai T. , Teng F. , Guo R. , Li W. , Zhou Q (2014) **One-step generation of knockout pigs by zygote injection of CRISPR/Cas system** *Cell Res* 24:372–375

- Haidet A. M. , Rizo L. , Handy C. , Umapathi P. , Eagle A. , Shilling C. , Boue D. , Martin P. T. , Sahenk Z. , Mendell J. R. , Kaspar B. K (2008) **Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors** *Proc Natl Acad Sci U S A* **105**:4318–4322
- Han J. , Forrest R. H. , Hickford J. G (2013) **Genetic variations in the myostatin gene (MSTN) in New Zealand sheep breeds** *Mol Biol Rep* **40**:6379–6384
- Hanset R. , Michaux C. (1985) **On the genetic determinism of muscular hypertrophy in the Belgian White and Blue cattle breed. I. Experimental data** *Genet Sel Evol* (1983) **17**:359–368
- Hebert J. M. , Rosenquist T. , Gotz J. , Martin G. R (1994) **FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations** *Cell* **78**:1017–1025
- Higgins C. A. , Petukhova L. , Harel S. , Ho Y. Y. , Drill E. , Shapiro L. , Wajid M. , Christiano A. M (2014) **FGF5 is a crucial regulator of hair length in humans** *Proc Natl Acad Sci U S A* **111**:10648–10653
- Hongbing HAN Y. M. , Tao WANG , Ling LIAN , Xiuzhi TIAN , Rui HU , Shoulong DENG , Kongpan LI , Feng WANG , Ning LI , Guoshi LIU , Yaofeng ZHAO , Zhengxing LIAN (2014) **One-step generation of myostatin gene knockout sheep via the CRISPR/Cas9 system** *Front. Agr. Sci. Eng* **1**:2–5
- Huang Z. , Chen D. , Zhang K. , Yu B. , Chen X. , Meng J (2007) **Regulation of myostatin signaling by c-Jun N-terminal kinase in C2C12 cells** *Cell Signal* **19**:2286–2295
- Joulia D. , Bernardi H. , Garandel V. , Rabenoelina F. , Vernus B. , Cabello G (2003) **Mechanisms involved in the inhibition of myoblast proliferation and differentiation by myostatin** *Experimental cell research* **286**:263–275
- Kambadur R. , Sharma M. , Smith T. P. , Bass J. J (1997) **Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle** *Genome Res* **7**:910–916
- Kehler J. S. , David V. A. , Schaffer A. A. , Bajema K. , Eizirik E. , Ryugo D. K. , Hannah S. S. , O'Brien S. J. , Menotti-Raymond M (2007) **Four independent mutations in the feline fibroblast growth factor 5 gene determine the long-haired phenotype in domestic cats** *Hered* **98**:555–566
- Kijas J. W. , McCulloch R. , Edwards J. E. , Oddy V. H. , Lee S. H. , van der Werf J. (2007) **Evidence for multiple alleles effecting muscling and fatness at the ovine GDF8 locus** *BMC Genet* **8**
- Kotani H. , Taimatsu K. , Ohga R. , Ota S. , Kawahara A (2015) **Efficient Multiple Genome Modifications Induced by the crRNAs, tracrRNA and Cas9 Protein Complex in Zebrafish** *PLoS One* **10**
- Lamarche E. , AlSudais H. , Rajgara R. , Fu D. , Omaiche S. , Wiper-Bergeron N (2021) **SMAD2 promotes myogenin expression and terminal myogenic differentiation** *Development* **148**

Langley B. , Thomas M. , Bishop A. , Sharma M. , Gilmour S. , Kambadur R (2002) **Myostatin inhibits myoblast differentiation by down-regulating MyoD expression** *J Biol Chem* **277**:49831–49840

Lee S. J (2021) **Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction** *J Clin Invest* **131**

Legrand R. , Tiret L. , Abitbol M (2014) **Two recessive mutations in FGF5 are associated with the long-hair phenotype in donkeys** *Genet Sel Evol* **46**

Li L. , Chambard J. C. , Karin M. , Olson E. N (1992) **Fos and Jun repress transcriptional activation by myogenin and MyoD: the amino terminus of Jun can mediate repression** *Genes Dev* **6**:676–689

Liu X. , Manzano G. , Lovett D. H. , Kim H. T (2010) **Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional regulation in skeletal muscle atrophy** *Biochem Biophys Res Commun* **396**:219–223

Lv Q. , Yuan L. , Deng J. , Chen M. , Wang Y. , Zeng J. , Li Z. , Lai L (2016) **Efficient Generation of Myostatin Gene Mutated Rabbit by CRISPR/Cas9** *Sci Rep* **6**

Marchitelli C. , Savarese M. C. , Crisa A. , Nardone A. , Marsan P. A. , Valentini A (2003) **Double muscling in Marchigiana beef breed is caused by a stop codon in the third exon of myostatin gene** *Mamm Genome* **14**:392–395

Marques C. , Unterkircher T. , Kroon P. , Oldrini B. , Izzo A. , Dramaretska Y. , Ferrarese R. , Kling E. , Schnell O. , Nelander S. , Wagner E. F. , Bakiri L. , Gargiulo G. , Carro M. S. , Squatrito M (2021) **NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1** *Elife* **10**

Mathes S. , Fahrner A. , Ghoshdastider U. , Rudiger H. A. , Leunig M. , Wolfrum C. , Krutzfeldt J (2021) **FGF-2-dependent signaling activated in aged human skeletal muscle promotes intramuscular adipogenesis** *Proc Natl Acad Sci U S A* **118**

McCroskery S. , Thomas M. , Maxwell L. , Sharma M. , Kambadur R (2003) **Myostatin negatively regulates satellite cell activation and self-renewal** *Journal of Cell Biology* **162**:1135–1147

McPherron A. C. , Lawler A. M. , Lee S. J (1997) **Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member** *Nature* **387**:83–90

Morissette M. R. , Cook S. A. , Buranasombati C. , Rosenberg M. A. , Rosenzweig A (2009) **Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt** *Am J Physiol Cell Physiol* **297**:C1124–1132

Nishi M. , Yasue A. , Nishimatu S. , Nohno T. , Yamaoka T. , Itakura M. , Moriyama K. , Ohuchi H. , Noji S (2002) **A missense mutant myostatin causes hyperplasia without hypertrophy in the mouse muscle** *Biochem Biophys Res Commun* **293**:247–251

Niu Y. , Shen B. , Cui Y. , Chen Y. , Wang J. , Wang L. , Kang Y. , Zhao X. , Si W. , Li W. , Xiang A. P. , Zhou J. , Guo X. , Bi Y. , Si C. , Hu B. , Dong G. , Wang H. , Zhou Z. , Li T. , Tan T. , Pu X. , Wang F. , Ji S. , Zhou Q. , Huang X. , Ji W. , Sha J (2014) **Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos** *Cell* **156**:836–843

Pothuraju M. , Mishra S. K. , Kumar S. N. , Mohamed N. F. , Kataria R. S. , Yadav D. K. , Arora R (2015) **Polymorphism in the Coding Region Sequence of Gdf8 Gene in Indian Sheep** *Genetika* **51**:1297–1300

Puntschart A. , Wey E. , Jostarndt K. , Vogt M. , Wittwer M. , Widmer H. R. , Hoppeler H. , Billeter R (1998) **Expression of fos and jun genes in human skeletal muscle after exercise** *Am J Physiol* **274**:C129–137

Qian L. , Tang M. , Yang J. , Wang Q. , Cai C. , Jiang S. , Li H. , Jiang K. , Gao P. , Ma D. , Chen Y. , An X. , Li K. , Cui W (2015) **Targeted mutations in myostatin by zinc-finger nucleases result in double-muscling phenotype in Meishan pigs** *Sci Rep* **5**

Sato M. , Koriyama M. , Watanabe S. , Ohtsuka M. , Sakurai T. , Inada E. , Saitoh I. , Nakamura S. , Miyoshi K (2015) **Direct Injection of CRISPR/Cas9-Related mRNA into Cytoplasm of Parthenogenetically Activated Porcine Oocytes Causes Frequent Mosaicism for Indel Mutations** *Int J Mol Sci* **16**:17838–17856

Sjakste T. , Paramonova N. , Grislis Z. , Trapina I. , Kairisa D (2011) **Analysis of the single-nucleotide polymorphism in the 5'UTR and part of intron I of the sheep MSTN gene** *DNA Cell Biol* **30**:433–444

Sobolev V. V. , Khashukoeva A. Z. , Evina O. E. , Geppe N. A. , Chebysheva S. N. , Korsunskaya I. M. , Tchepourina E. , Mezentsev A (2022) **Role of the Transcription Factor FOSL1 in Organ Development and Tumorigenesis** *Int J Mol Sci* **23**

Sundberg J. P. , Rourk M. H. , Boggess D. , Hogan M. E. , Sundberg B. A. , Bertolino A. P (1997) **Angora mouse mutation: altered hair cycle, follicular dystrophy, phenotypic maintenance of skin grafts, and changes in keratin expression** *Vet Pathol* **34**:171–179

Sung Y. H. , Kim J. M. , Kim H. T. , Lee J. , Jeon J. , Jin Y. , Choi J. H. , Ban Y. H. , Ha S. J. , Kim C. H. , Lee H. W. , Kim J. S (2014) **Highly efficient gene knockout in mice and zebrafish with RNA-guided endonucleases** *Genome Res* **24**:125–131

Talotta F. , Casalino L. , Verde P (2020) **The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications' door** *Oncogene* **39**:4491–4506

Taylor W. E. , Bhasin S. , Artaza J. , Byhower F. , Azam M. , Willard D. H. , Kull F. C. , Gonzalez-Cadavid N (2001) **Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells** *Am J Physiol Endocrinol Metab* **280**:E221–228

Thomas M. , Langley B. , Berry C. , Sharma M. , Kirk S. , Bass J. , Kambadur R (2000) **Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation** *Journal of Biological Chemistry* **275**:40235–40243

Thomas M. , Langley B. , Berry C. , Sharma M. , Kirk S. , Bass J. , Kambadur R (2000) **Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation** / *Biol Chem* **275**:40235–40243

Tobin S. W. , Yang D. , Girgis J. , Farahzad A. , Blais A. , McDermott J. C (2016) **Regulation of Hspb7 by MEF2 and AP-1: implications for Hspb7 in muscle atrophy** / *J Cell Sci* **129**:4076–4090

Tu Z. , Yang W. , Yan S. , Yin A. , Gao J. , Liu X. , Zheng Y. , Zheng J. , Li Z. , Yang S. , Li S. , Guo X. , Li X. J (2017) **Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos** / *Sci Rep* **7**

Wan H. , Feng C. , Teng F. , Yang S. , Hu B. , Niu Y. , Xiang A. P. , Fang W. , Ji W. , Li W. , Zhao X. , Zhou Q (2015) **One-step generation of p53 gene biallelic mutant Cynomolgus monkey via the CRISPR/Cas system** / *Cell Res* **25**:258–261

Wang H. , Yang H (2019) **Gene-edited babies: What went wrong and what could go wrong** / *PLoS Biol* **17**

Wang H. , Yang H. , Shivalila C. S. , Dawlaty M. M. , Cheng A. W. , Zhang F. , Jaenisch R (2013) **One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering** / *Cell* **153**:910–918

Wang Q. , McPherron A. C (2012) **Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation** / *J Physiol* **590**:2151–2165

Wang X. , Yu H. , Lei A. , Zhou J. , Zeng W. , Zhu H. , Dong Z. , Niu Y. , Shi B. , Cai B. , Liu J. , Huang S. , Yan H. , Zhao X. , Zhou G. , He X. , Chen X. , Yang Y. , Jiang Y. , Shi L. , Tian X. , Wang Y. , Ma B. , Huang X. , Qu L. , Chen Y (2015) **Generation of gene-modified goats targeting MSTN and FGF5 via zygote injection of CRISPR/Cas9 system** / *Sci Rep* **5**

Wang Y. , Ma C. , Sun Y. , Li Y. , Kang L. , Jiang Y (2017) **Dynamic transcriptome and DNA methylome analyses on longissimus dorsi to identify genes underlying intramuscular fat content in pigs** / *BMC Genomics* **18**

Wegner J. , Albrecht E. , Fiedler I. , Teuscher F. , Papstein H. J. , Ender K (2000) **Growth- and breed-related changes of muscle fiber characteristics in cattle** / *J Anim Sci* **78**:1485–1496

Wijaya Y. T. , Setiawan T. , Sari I. N. , Park K. , Lee C. H. , Cho K. W. , Lee Y. K. , Lim J. Y. , Yoon J. K. , Lee S. H. , Kwon H. Y (2022) **Ginsenoside Rd ameliorates muscle wasting by suppressing the signal transducer and activator of transcription 3 pathway** / *Cachexia Sarcopenia Muscle*

Xu T. S. , Gu L. H. , Zhang X. H. , Ye B. G. , Liu X. L. , Hou S. S (2013) **Characterization of myostatin gene (MSTN) of Pekin duck and the association of its polymorphism with breast muscle traits** / *Genet Mol Res* **12**:3166–3177

Xu Y. , Liu H. , Pan H. , Wang X. , Zhang Y. , Yao B. , Li N. , Lai L. , Li Z (2020) **CRISPR/Cas9-mediated Disruption of Fibroblast Growth Factor 5 in Rabbits Results in a Systemic Long Hair Phenotype by Prolonging Anagen** / *Genes (Basel)* **11**

Yoshizawa Y. , Wada K. , Shimoi G. , Kameyama Y. , Wakabayashi Y. , Fukuta K. , Hashizume R (2015) **A 1-bp deletion in *Fgf5* causes male-dominant long hair in the Syrian hamster** *Mamm Genome* **26**:630–637

Zhang R. , Li Y. , Jia K. , Xu X. , Li Y. , Zhao Y. , Zhang X. , Zhang J. , Liu G. , Deng S. , Lian Z (2020) **Crosstalk between androgen and Wnt/beta-catenin leads to changes of wool density in FGF5-knockout sheep** *Cell Death Dis* **11**

Zhiliang G. , Dahai Z. , Ning L. , Hui L. , Xuemei D. , Changxin W (2004) **The single nucleotide polymorphisms of the chicken myostatin gene are associated with skeletal muscle and adipose growth** *Sci China C Life Sci* **47**:25–30

Zhou J. , Wang J. , Shen B. , Chen L. , Su Y. , Yang J. , Zhang W. , Tian X. , Huang X (2014) **Dual sgRNAs facilitate CRISPR/Cas9-mediated mouse genome targeting** *FEBS J* **281**:1717–1725

Zhu X. , Hadhazy M. , Wehling M. , Tidball J. G. , McNally E. M (2000) **Dominant negative myostatin produces hypertrophy without hyperplasia in muscle** *FEBS Lett* **474**:71–75

Author information

Ming-Ming Chen

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

ORCID iD: [0000-0003-2059-6342](https://orcid.org/0000-0003-2059-6342)

Yue Zhao

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

Xue-Ling Xu

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

Xiao-Sheng Zhang

Institute of Animal Husbandry and Veterinary Medicine, Tianjin Academy of Agricultural Sciences, Tianjin 300381, China

Jin-Long Zhang

Institute of Animal Husbandry and Veterinary Medicine, Tianjin Academy of Agricultural Sciences, Tianjin 300381, China

Su-Jun Wu

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

Zhi-Mei Liu

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

Yi-Ming Yuan

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

Xiao-Fei Guo

Institute of Animal Husbandry and Veterinary Medicine, Tianjin Academy of Agricultural Sciences, Tianjin 300381, China

Shi-Yu Qi

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

Guang Yi

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

Shu-Qi Wang

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

Huang-Xiang Li

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

Ao-Wu Wu

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

Guo-Shi Liu

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

ORCID iD: [0000-0002-5688-3645](https://orcid.org/0000-0002-5688-3645)

Kun Yu

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

Shoulong Deng

NHC Key Laboratory of Human Disease Comparative Medicine, Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China

Hong-Bing Han

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

ORCID iD: [0000-0002-6671-719X](https://orcid.org/0000-0002-6671-719X)

Feng-Hua Lv

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

For correspondence: lvfenghua@cau.edu.cn

Yan Li

Laboratory Animal Center of the Academy of Military Medical Sciences, Beijing 100071, China

For correspondence: scauly@cau.edu.cn

Zheng-Xing Lian

Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China

For correspondence: lianzhx@cau.edu.cn

Editors

Reviewing Editor

Shahragim Tajbakhsh

Institut Pasteur, France

Joint Public Review:

Chen and collaborators first analysed in sheep embryonic gene editing using CRISPR-Cas9 technology to invalidate the two alleles of *Mstn* and *Fgf5* genes by using different ratios of Cas9 mRNA and sgRNA. They showed that a ratio of 1:10 had highest efficiency and they successfully generated two sheep with biallelic mutations of both genes. Materials and Methods on the generation of gene edited sheep is entirely missing. The data on these gene edited sheep have been already published twice by the authors in different contexts. Other groups reported on gene editing of *Mstn* or *Fgf5* in sheep embryos and the resulting phenotypes.

Although the findings are interesting, they do not provide sufficiently new scientific information or advancements in producing genetically modified livestock with improved production characteristics. While the *MSTN*Δ273 sheep exhibited an increased number of muscle fibers, the data provided did not demonstrate a significant improvement in meat productions, quality or quantity in the *MSTN*Δ273 sheep vs WT.

The authors indicate that sgRNA design changes in addition to changing the molar ratio of Cas9 mRNA:sgRNA improved the ability to generate biallelic homozygous mutant sheep; however, the data provided to not demonstrate any significant difference. Given the small number of sheep that were actually produced and evaluated, it is extremely difficult to demonstrate anything that was analyzed to be significantly (statistically) different between *MSTN*Δ273 sheep and WT, yet the authors seem to ignore this in much of their discussion. There is no explanation as to why the authors started with sheep that were *FGF5* knockouts. The reviewer assumes that this was simply a line of sheep available from previous studies and the goal was to produce sheep with both improved hair/wool characteristics in addition to improved muscle development. However, the use of *FGF5* knockout sheep complicates the ability to accurately decipher the unique aspects associated with targeting only myostatin for knock-out. At minimum, this is a variable that has to be considered in the statistical analysis. No information is provided on the methods used to produce the *MSTN*Δ273 sheep, which is fundamentally important. It is assumed they were produced by injecting one-cell zygotes then transferring these into surrogate females. The methods employed might have a profound effect on the outcome.

Authors genotyped one sheep with a biallelic three base pair deletion in *Mstn* exon 3 and a compound heterozygote mutation in *Fgf5* with a 5 nucleotides deletion on one allele and 37 nucleotides deletion on the other allele, partially spanning over the same region. This sheep developed a double muscle phenotype, which was documented using photography and CT scan. The hair phenotype was not further addressed, but authors referred to a previous publication.

Authors performed morphometric studies on two distinct muscles, longissimus dorsi and gluteus medius, and found a profound fiber hypotrophy in the *Mstn*^{-/-};*Fgf5*^{-/-} double mutants, with a shift from larger fiber diameter to smaller fiber sizes. Morphometric studies showed only a low percentage of fibers in wt and mutant sheep had fiber cross sectional areas larger than 800 μm², whereas about 30% in wt and about 60% in the mutant had CSA of <400 μm². The report of one case, without reproducing the phenotype in other sheep, is scientifically insufficient. The fiber sizes in wt sheep remains far below previously published reports in sheep (about 3-5 times smaller) and as compared to other species, which suggests a methodological error in morphometric methods.

The authors also investigated the influence of *Fgf5* mutation on muscle development. They determined fiber cross sectional area in heterozygous *Fgf5* mutant (number of investigated animals not given) and conclude that *Mstn* mutation but not *Fgf5* mutation caused the double muscle phenotype. Results are insufficient to support this conclusion. Firstly, authors investigated heterozygous *FGF5* sheep and not homozygous mutants. Secondly, *FGF5* has previously been shown to stimulate expansion of connective tissue fibroblasts and to inhibit skeletal muscle development during limb embryonic development (Clase et al. 2000). Of note, *Mstn* is also expressed during embryonic development. A combined knockout could therefore entail synergistic effects and cause muscle hyperplasia that is not found in individual knockout, a hypothesis that was not addressed by the authors.

The authors generated and studied an F1 generation of mutant sheep with heterozygous mutation in *Mstn* and *Fgf5*. In *Mstn*^{+/-};*Fgf5*^{+/-}, gluteus medius muscle was found to be larger compared to wt sheep, whereas other muscles were smaller, and overall meat quantity did not change. Morphometric studies revealed a similar muscle fiber hypotrophy and muscle hyperplasia as in the *Mstn*^{-/-};*Fgf5*^{-/-} gluteus muscle.

In the next part of results, authors investigated the presence of myostatin protein in homozygous *Mstn* muscle using immunohistochemistry and found no differences compared to wt, however, positive and negative controls are missing. The also determined *Mstn* transcription and protein quantity using WB in heterozygous *Mstn* muscle and found no difference. The authors did not provide data to explain of why the herein generated *Mstn* mutation causes muscle fiber hypotrophy, whereas most work on myostatin abrogation demonstrated fiber hypertrophy.

Authors then isolated myoblasts from hind limbs of 3-month-old sheep fetuses and cultured in presence of 20% fetal bovine serum before switching to differentiation medium containing 2% horse serum. The cultures showed increased proliferation of *Mstn*^{+/-};*Fgf5*^{+/-} myoblasts as well as downregulation of genes associated with muscle differentiation as well as reduced fusion index. No experiments were performed to assure whether the myostatin and *FGF5* pathways were inhibited. No control experiments using supplementation with recombinant proteins and using growth factor depleted culture supplements were performed. As *FGF5* and myostatin are secreted factors, evidence is missing whether this led to conditioning of the culture medium. Of note, previous work in mice demonstrated that the double muscle phenotype developed independent of satellite cells activity (Amthor et al. 2009).

Authors then performed RNA seq from *Mstn*^{+/-};*Fgf5*^{+/-} muscle and found a number of differentially expressed genes, but none has been previously reported being involved in the myostatin signaling pathway, so the authors chose to only focus on *FOSL1* and associated genes. Authors then demonstrated that *Pdpn* and *Ankrd2* were upregulated during myogenic differentiation, whereas *FOPSL1* was downregulated. Moreover, *Fosl1* transcription was upregulated in myoblasts and myotubes from *Mstn*^{+/-};*Fgf5*^{+/-} muscle. Authors showed an interaction between *Fosl1* and *Myod1*. Moreover, authors demonstrated that *Pols1* directly binds to the *Myod1* promoter. Authors also found decreased p38 MAPK protein levels in proliferating myoblasts from *Mstn*^{+/-};*Fgf5*^{+/-} muscle and increased p38 MAPK in differentiating myotubes.

Furthermore, gain-of-function by overexpressing *FOSL1* promoted cell proliferation and inhibited differentiation, and tert-butylhydroquinone, an indirect activator of *FOSL1* also inhibited myogenic differentiation. The findings do not support the idea that *FOSL1* is not involved, but neither do they strongly support the involvement of *FOSL1*. The observations made by the authors could be co-incidental and not causative in nature.

The manuscript by Chen et al. demonstrated successful gene editing in sheep embryos to obtain biallelic mutation of *Mstn* and *FGF5*. The resulting double muscle phenotype resulted from fiber hypotrophy and hyperplasia, which contradicts findings in the literature. Chen et al. generated F1 heterozygous offsprings, in which *Mstn* transcription and translation did not change. Myoblasts from these animals showed increased proliferation and decreased differentiation, which authors interpreted as the underlying cellular mechanism of the double muscle phenotype. However, no work on muscle development in these animals is presented. Important in vitro control experiments are missing. Chen and collaborators found *Fosl1* as a differentially expressed gene in *Mstn*^{+/-};*Fgf5*^{+/-} muscle. *Fosl1* drives myoblast proliferation and has direct regulatory effect on the *Myod1* promoter. The cellular and molecular mechanism of *Fosl1* during myogenesis is novel and solid evidence. However, data remain inadequate to conclude whether *Fosl1* indeed acts downstream of myostatin.

As the significant findings are minimal, the amount of text provided, figures and tables are disproportionally excessive. A large number of different molecular techniques are employed to try and decipher the mechanism(s) that result in the observed phenotype = double muscling. The authors focus on the MEK-ERK-FOSL1 pathway and suggest this the key pathway/mechanism resulting in the phenotype observed in *MSTN*^{Del273}sheep. However, they provide very little solid evidence to support this notion.

The manuscript is very long, complicated and difficult to read, given the minimum amount of significant information that is provided. Further, it misses information in material methods, on the generation of animals, on histological techniques and morphometric studies. There is no information provided on the sex of the animals produced and then analyzed. There are also a number of editorial mistakes e.g. the authors refer to tables S1-S4 in the materials and methods and results section, but and there is no table S1-S4 provided.